ARTICLE | Company News
MacroGenics, J&J deal
January 5, 2015 8:00 AM UTC
MacroGenics will grant Johnson & Johnson’s Janssen Biotech Inc. unit exclusive, worldwide rights to preclinical candidate MGD011. The compound is a bispecific antibody against CD19 and CD3 developed...